nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CYP2C8—Levothyroxine—hypothyroidism	0.0684	0.227	CbGbCtD
Nilotinib—CYP2C8—Liotrix—hypothyroidism	0.0667	0.222	CbGbCtD
Nilotinib—ABCB1—Levothyroxine—hypothyroidism	0.0463	0.154	CbGbCtD
Nilotinib—ABCB1—Liothyronine—hypothyroidism	0.0463	0.154	CbGbCtD
Nilotinib—ABCB1—Liotrix—hypothyroidism	0.0452	0.15	CbGbCtD
Nilotinib—CYP3A4—Levothyroxine—hypothyroidism	0.0277	0.0922	CbGbCtD
Nilotinib—Hyperthyroidism—Dextrothyroxine—hypothyroidism	0.00726	0.0336	CcSEcCtD
Nilotinib—Hyperthyroidism—Levothyroxine—hypothyroidism	0.00726	0.0336	CcSEcCtD
Nilotinib—Hyperphosphataemia—Liotrix—hypothyroidism	0.00618	0.0286	CcSEcCtD
Nilotinib—Hyperthyroidism—Liotrix—hypothyroidism	0.00534	0.0247	CcSEcCtD
Nilotinib—Swelling face—Liotrix—hypothyroidism	0.00443	0.0205	CcSEcCtD
Nilotinib—Angina pectoris—Liothyronine—hypothyroidism	0.00357	0.0165	CcSEcCtD
Nilotinib—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00322	0.0149	CcSEcCtD
Nilotinib—Myocardial infarction—Liothyronine—hypothyroidism	0.0032	0.0148	CcSEcCtD
Nilotinib—Cyanosis—Liotrix—hypothyroidism	0.00298	0.0138	CcSEcCtD
Nilotinib—Wheezing—Levothyroxine—hypothyroidism	0.00279	0.0129	CcSEcCtD
Nilotinib—Wheezing—Dextrothyroxine—hypothyroidism	0.00279	0.0129	CcSEcCtD
Nilotinib—Feeling hot—Liotrix—hypothyroidism	0.00269	0.0124	CcSEcCtD
Nilotinib—Arrhythmia—Liothyronine—hypothyroidism	0.00262	0.0121	CcSEcCtD
Nilotinib—Disorientation—Dextrothyroxine—hypothyroidism	0.00233	0.0108	CcSEcCtD
Nilotinib—Disorientation—Levothyroxine—hypothyroidism	0.00233	0.0108	CcSEcCtD
Nilotinib—Hypocalcaemia—Liotrix—hypothyroidism	0.00231	0.0107	CcSEcCtD
Nilotinib—Creatinine increased—Liotrix—hypothyroidism	0.00222	0.0103	CcSEcCtD
Nilotinib—Increased appetite—Dextrothyroxine—hypothyroidism	0.00222	0.0103	CcSEcCtD
Nilotinib—Increased appetite—Levothyroxine—hypothyroidism	0.00222	0.0103	CcSEcCtD
Nilotinib—Hypertension—Liothyronine—hypothyroidism	0.00221	0.0102	CcSEcCtD
Nilotinib—Hypoglycaemia—Dextrothyroxine—hypothyroidism	0.00213	0.00988	CcSEcCtD
Nilotinib—Cardiac failure—Dextrothyroxine—hypothyroidism	0.00213	0.00988	CcSEcCtD
Nilotinib—Hypoglycaemia—Levothyroxine—hypothyroidism	0.00213	0.00988	CcSEcCtD
Nilotinib—Cardiac failure—Levothyroxine—hypothyroidism	0.00213	0.00988	CcSEcCtD
Nilotinib—Wheezing—Liotrix—hypothyroidism	0.00205	0.00949	CcSEcCtD
Nilotinib—Tachycardia—Liothyronine—hypothyroidism	0.00203	0.00942	CcSEcCtD
Nilotinib—Fluid retention—Liotrix—hypothyroidism	0.002	0.00928	CcSEcCtD
Nilotinib—Blood urea increased—Liotrix—hypothyroidism	0.00199	0.00923	CcSEcCtD
Nilotinib—Hypotension—Liothyronine—hypothyroidism	0.00195	0.00902	CcSEcCtD
Nilotinib—Dehydration—Levothyroxine—hypothyroidism	0.00194	0.00897	CcSEcCtD
Nilotinib—Dehydration—Dextrothyroxine—hypothyroidism	0.00194	0.00897	CcSEcCtD
Nilotinib—Muscular weakness—Dextrothyroxine—hypothyroidism	0.00184	0.0085	CcSEcCtD
Nilotinib—Muscular weakness—Levothyroxine—hypothyroidism	0.00184	0.0085	CcSEcCtD
Nilotinib—Sepsis—Liotrix—hypothyroidism	0.00183	0.00848	CcSEcCtD
Nilotinib—Angina pectoris—Levothyroxine—hypothyroidism	0.00175	0.00812	CcSEcCtD
Nilotinib—Angina pectoris—Dextrothyroxine—hypothyroidism	0.00175	0.00812	CcSEcCtD
Nilotinib—Disorientation—Liotrix—hypothyroidism	0.00171	0.00793	CcSEcCtD
Nilotinib—Body temperature increased—Liothyronine—hypothyroidism	0.00165	0.00763	CcSEcCtD
Nilotinib—Increased appetite—Liotrix—hypothyroidism	0.00163	0.00755	CcSEcCtD
Nilotinib—Weight decreased—Dextrothyroxine—hypothyroidism	0.00163	0.00754	CcSEcCtD
Nilotinib—Weight decreased—Levothyroxine—hypothyroidism	0.00163	0.00754	CcSEcCtD
Nilotinib—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00158	0.00733	CcSEcCtD
Nilotinib—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00158	0.00733	CcSEcCtD
Nilotinib—Myocardial infarction—Levothyroxine—hypothyroidism	0.00157	0.00728	CcSEcCtD
Nilotinib—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00157	0.00728	CcSEcCtD
Nilotinib—Hypoglycaemia—Liotrix—hypothyroidism	0.00157	0.00727	CcSEcCtD
Nilotinib—Cardiac failure—Liotrix—hypothyroidism	0.00157	0.00727	CcSEcCtD
Nilotinib—Blood creatinine increased—Liotrix—hypothyroidism	0.00144	0.00665	CcSEcCtD
Nilotinib—Dehydration—Liotrix—hypothyroidism	0.00143	0.0066	CcSEcCtD
Nilotinib—Hypokalaemia—Liotrix—hypothyroidism	0.00139	0.00646	CcSEcCtD
Nilotinib—Muscular weakness—Liotrix—hypothyroidism	0.00135	0.00626	CcSEcCtD
Nilotinib—Flushing—Dextrothyroxine—hypothyroidism	0.00134	0.00619	CcSEcCtD
Nilotinib—Flushing—Levothyroxine—hypothyroidism	0.00134	0.00619	CcSEcCtD
Nilotinib—Abdominal distension—Liotrix—hypothyroidism	0.00133	0.00617	CcSEcCtD
Nilotinib—Angina pectoris—Liotrix—hypothyroidism	0.00129	0.00597	CcSEcCtD
Nilotinib—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00129	0.00596	CcSEcCtD
Nilotinib—Arrhythmia—Levothyroxine—hypothyroidism	0.00129	0.00596	CcSEcCtD
Nilotinib—Bronchitis—Liotrix—hypothyroidism	0.00127	0.0059	CcSEcCtD
Nilotinib—Alopecia—Levothyroxine—hypothyroidism	0.00127	0.00589	CcSEcCtD
Nilotinib—Alopecia—Dextrothyroxine—hypothyroidism	0.00127	0.00589	CcSEcCtD
Nilotinib—Weight decreased—Liotrix—hypothyroidism	0.0012	0.00555	CcSEcCtD
Nilotinib—Tremor—Dextrothyroxine—hypothyroidism	0.00118	0.00544	CcSEcCtD
Nilotinib—Tremor—Levothyroxine—hypothyroidism	0.00118	0.00544	CcSEcCtD
Nilotinib—Acute coronary syndrome—Liotrix—hypothyroidism	0.00116	0.00539	CcSEcCtD
Nilotinib—Renal failure—Liotrix—hypothyroidism	0.00116	0.00537	CcSEcCtD
Nilotinib—Myocardial infarction—Liotrix—hypothyroidism	0.00116	0.00536	CcSEcCtD
Nilotinib—Palpitations—Levothyroxine—hypothyroidism	0.00111	0.00513	CcSEcCtD
Nilotinib—Palpitations—Dextrothyroxine—hypothyroidism	0.00111	0.00513	CcSEcCtD
Nilotinib—Arthralgia—Levothyroxine—hypothyroidism	0.00107	0.00494	CcSEcCtD
Nilotinib—Arthralgia—Dextrothyroxine—hypothyroidism	0.00107	0.00494	CcSEcCtD
Nilotinib—Anxiety—Levothyroxine—hypothyroidism	0.00106	0.00493	CcSEcCtD
Nilotinib—Anxiety—Dextrothyroxine—hypothyroidism	0.00106	0.00493	CcSEcCtD
Nilotinib—Hypoaesthesia—Liotrix—hypothyroidism	0.00105	0.00488	CcSEcCtD
Nilotinib—EPHB3—adrenal gland—hypothyroidism	0.00104	0.00382	CbGeAlD
Nilotinib—CYP2D6—urine—hypothyroidism	0.00103	0.0038	CbGeAlD
Nilotinib—Confusional state—Levothyroxine—hypothyroidism	0.00103	0.00478	CcSEcCtD
Nilotinib—Confusional state—Dextrothyroxine—hypothyroidism	0.00103	0.00478	CcSEcCtD
Nilotinib—EPHA2—adrenal cortex—hypothyroidism	0.00103	0.00379	CbGeAlD
Nilotinib—TIE1—female gonad—hypothyroidism	0.00102	0.00374	CbGeAlD
Nilotinib—EPHB4—heart—hypothyroidism	0.00102	0.00374	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—hypothyroidism	0.00101	0.00372	CbGeAlD
Nilotinib—BRAF—thyroid gland—hypothyroidism	0.00101	0.00372	CbGeAlD
Nilotinib—Shock—Dextrothyroxine—hypothyroidism	0.00101	0.00466	CcSEcCtD
Nilotinib—Shock—Levothyroxine—hypothyroidism	0.00101	0.00466	CcSEcCtD
Nilotinib—FGR—cardiovascular system—hypothyroidism	0.00101	0.0037	CbGeAlD
Nilotinib—TEK—adrenal cortex—hypothyroidism	0.001	0.0037	CbGeAlD
Nilotinib—Tachycardia—Levothyroxine—hypothyroidism	0.000999	0.00463	CcSEcCtD
Nilotinib—Tachycardia—Dextrothyroxine—hypothyroidism	0.000999	0.00463	CcSEcCtD
Nilotinib—EPHA2—heart—hypothyroidism	0.000996	0.00367	CbGeAlD
Nilotinib—EPHA4—gonad—hypothyroidism	0.000995	0.00366	CbGeAlD
Nilotinib—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00099	0.00458	CcSEcCtD
Nilotinib—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00099	0.00458	CcSEcCtD
Nilotinib—MAPK8—liver—hypothyroidism	0.000984	0.00362	CbGeAlD
Nilotinib—Flushing—Liotrix—hypothyroidism	0.000984	0.00455	CcSEcCtD
Nilotinib—BRAF—female gonad—hypothyroidism	0.000976	0.00359	CbGeAlD
Nilotinib—TEK—heart—hypothyroidism	0.000972	0.00358	CbGeAlD
Nilotinib—EPHA4—pituitary gland—hypothyroidism	0.00097	0.00357	CbGeAlD
Nilotinib—EPHB3—female gonad—hypothyroidism	0.000968	0.00356	CbGeAlD
Nilotinib—MAPK8—cerebellum—hypothyroidism	0.000961	0.00354	CbGeAlD
Nilotinib—CA3—pituitary gland—hypothyroidism	0.000959	0.00353	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—hypothyroidism	0.000958	0.00353	CbGeAlD
Nilotinib—HCK—adrenal gland—hypothyroidism	0.000954	0.00351	CbGeAlD
Nilotinib—HCK—blood—hypothyroidism	0.000954	0.00351	CbGeAlD
Nilotinib—ABL2—adrenal gland—hypothyroidism	0.000948	0.00349	CbGeAlD
Nilotinib—ABL2—blood—hypothyroidism	0.000948	0.00349	CbGeAlD
Nilotinib—Arrhythmia—Liotrix—hypothyroidism	0.000947	0.00438	CcSEcCtD
Nilotinib—MAP4K1—testis—hypothyroidism	0.000946	0.00348	CbGeAlD
Nilotinib—EPHA2—cardiovascular system—hypothyroidism	0.00094	0.00346	CbGeAlD
Nilotinib—Alopecia—Liotrix—hypothyroidism	0.000937	0.00434	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.000933	0.00432	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.000933	0.00432	CcSEcCtD
Nilotinib—EPHB6—heart—hypothyroidism	0.000929	0.00342	CbGeAlD
Nilotinib—Insomnia—Levothyroxine—hypothyroidism	0.000926	0.00429	CcSEcCtD
Nilotinib—Insomnia—Dextrothyroxine—hypothyroidism	0.000926	0.00429	CcSEcCtD
Nilotinib—HCK—thyroid gland—hypothyroidism	0.00092	0.00339	CbGeAlD
Nilotinib—TEK—cardiovascular system—hypothyroidism	0.000917	0.00337	CbGeAlD
Nilotinib—ABL2—thyroid gland—hypothyroidism	0.000915	0.00337	CbGeAlD
Nilotinib—Dyspnoea—Dextrothyroxine—hypothyroidism	0.000913	0.00423	CcSEcCtD
Nilotinib—Dyspnoea—Levothyroxine—hypothyroidism	0.000913	0.00423	CcSEcCtD
Nilotinib—Flatulence—Liotrix—hypothyroidism	0.000909	0.00421	CcSEcCtD
Nilotinib—LYN—liver—hypothyroidism	0.000908	0.00334	CbGeAlD
Nilotinib—Dysgeusia—Liotrix—hypothyroidism	0.000904	0.00418	CcSEcCtD
Nilotinib—TIE1—testis—hypothyroidism	0.000902	0.00332	CbGeAlD
Nilotinib—MAPK14—pituitary gland—hypothyroidism	0.000895	0.00329	CbGeAlD
Nilotinib—FGR—pituitary gland—hypothyroidism	0.000891	0.00328	CbGeAlD
Nilotinib—HCK—female gonad—hypothyroidism	0.000889	0.00327	CbGeAlD
Nilotinib—ABL2—female gonad—hypothyroidism	0.000884	0.00325	CbGeAlD
Nilotinib—Fatigue—Dextrothyroxine—hypothyroidism	0.000883	0.00409	CcSEcCtD
Nilotinib—Fatigue—Levothyroxine—hypothyroidism	0.000883	0.00409	CcSEcCtD
Nilotinib—PDGFRA—heart—hypothyroidism	0.00088	0.00324	CbGeAlD
Nilotinib—Vision blurred—Liotrix—hypothyroidism	0.00087	0.00403	CcSEcCtD
Nilotinib—EPHA4—adrenal gland—hypothyroidism	0.000867	0.00319	CbGeAlD
Nilotinib—EPHA4—blood—hypothyroidism	0.000867	0.00319	CbGeAlD
Nilotinib—BRAF—testis—hypothyroidism	0.000865	0.00318	CbGeAlD
Nilotinib—Tremor—Liotrix—hypothyroidism	0.000865	0.004	CcSEcCtD
Nilotinib—EPHB3—testis—hypothyroidism	0.000858	0.00316	CbGeAlD
Nilotinib—TIE1—liver—hypothyroidism	0.000853	0.00314	CbGeAlD
Nilotinib—EPHB4—pituitary gland—hypothyroidism	0.000848	0.00312	CbGeAlD
Nilotinib—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.000844	0.00391	CcSEcCtD
Nilotinib—Feeling abnormal—Levothyroxine—hypothyroidism	0.000844	0.00391	CcSEcCtD
Nilotinib—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.000837	0.00388	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.000837	0.00388	CcSEcCtD
Nilotinib—EPHA4—thyroid gland—hypothyroidism	0.000837	0.00308	CbGeAlD
Nilotinib—TIE1—cerebellum—hypothyroidism	0.000833	0.00307	CbGeAlD
Nilotinib—EPHA2—pituitary gland—hypothyroidism	0.000832	0.00306	CbGeAlD
Nilotinib—PDGFRA—cardiovascular system—hypothyroidism	0.000831	0.00306	CbGeAlD
Nilotinib—Syncope—Liotrix—hypothyroidism	0.000828	0.00383	CcSEcCtD
Nilotinib—CA3—thyroid gland—hypothyroidism	0.000826	0.00304	CbGeAlD
Nilotinib—MAP2K5—adrenal cortex—hypothyroidism	0.000821	0.00302	CbGeAlD
Nilotinib—BRAF—liver—hypothyroidism	0.000818	0.00301	CbGeAlD
Nilotinib—Palpitations—Liotrix—hypothyroidism	0.000815	0.00377	CcSEcCtD
Nilotinib—Urticaria—Levothyroxine—hypothyroidism	0.000813	0.00377	CcSEcCtD
Nilotinib—Urticaria—Dextrothyroxine—hypothyroidism	0.000813	0.00377	CcSEcCtD
Nilotinib—TEK—pituitary gland—hypothyroidism	0.000812	0.00299	CbGeAlD
Nilotinib—Loss of consciousness—Liotrix—hypothyroidism	0.000811	0.00375	CcSEcCtD
Nilotinib—Abdominal pain—Dextrothyroxine—hypothyroidism	0.000809	0.00375	CcSEcCtD
Nilotinib—Body temperature increased—Dextrothyroxine—hypothyroidism	0.000809	0.00375	CcSEcCtD
Nilotinib—Abdominal pain—Levothyroxine—hypothyroidism	0.000809	0.00375	CcSEcCtD
Nilotinib—Body temperature increased—Levothyroxine—hypothyroidism	0.000809	0.00375	CcSEcCtD
Nilotinib—EPHA4—female gonad—hypothyroidism	0.000808	0.00297	CbGeAlD
Nilotinib—CSF1R—adrenal cortex—hypothyroidism	0.000801	0.00295	CbGeAlD
Nilotinib—MAPK14—adrenal gland—hypothyroidism	0.000799	0.00294	CbGeAlD
Nilotinib—MAPK14—blood—hypothyroidism	0.000799	0.00294	CbGeAlD
Nilotinib—BRAF—cerebellum—hypothyroidism	0.000799	0.00294	CbGeAlD
Nilotinib—Hypertension—Liotrix—hypothyroidism	0.000797	0.00369	CcSEcCtD
Nilotinib—LCK—adrenal gland—hypothyroidism	0.000796	0.00293	CbGeAlD
Nilotinib—FGR—adrenal gland—hypothyroidism	0.000796	0.00293	CbGeAlD
Nilotinib—FGR—blood—hypothyroidism	0.000796	0.00293	CbGeAlD
Nilotinib—LCK—blood—hypothyroidism	0.000796	0.00293	CbGeAlD
Nilotinib—MAP2K5—heart—hypothyroidism	0.000794	0.00292	CbGeAlD
Nilotinib—EPHB3—cerebellum—hypothyroidism	0.000793	0.00292	CbGeAlD
Nilotinib—HCK—testis—hypothyroidism	0.000789	0.0029	CbGeAlD
Nilotinib—Chest pain—Liotrix—hypothyroidism	0.000786	0.00364	CcSEcCtD
Nilotinib—Arthralgia—Liotrix—hypothyroidism	0.000786	0.00364	CcSEcCtD
Nilotinib—ABL2—testis—hypothyroidism	0.000784	0.00288	CbGeAlD
Nilotinib—Anxiety—Liotrix—hypothyroidism	0.000783	0.00362	CcSEcCtD
Nilotinib—CA14—adrenal gland—hypothyroidism	0.000778	0.00286	CbGeAlD
Nilotinib—EPHB6—pituitary gland—hypothyroidism	0.000776	0.00286	CbGeAlD
Nilotinib—CSF1R—heart—hypothyroidism	0.000775	0.00285	CbGeAlD
Nilotinib—MAPK14—thyroid gland—hypothyroidism	0.000771	0.00284	CbGeAlD
Nilotinib—FGR—thyroid gland—hypothyroidism	0.000768	0.00283	CbGeAlD
Nilotinib—LCK—thyroid gland—hypothyroidism	0.000768	0.00283	CbGeAlD
Nilotinib—Confusional state—Liotrix—hypothyroidism	0.000759	0.00352	CcSEcCtD
Nilotinib—EPHB4—adrenal gland—hypothyroidism	0.000758	0.00279	CbGeAlD
Nilotinib—EPHB4—blood—hypothyroidism	0.000758	0.00279	CbGeAlD
Nilotinib—PDGFRA—gonad—hypothyroidism	0.000754	0.00277	CbGeAlD
Nilotinib—Oedema—Liotrix—hypothyroidism	0.000753	0.00349	CcSEcCtD
Nilotinib—MAP2K5—cardiovascular system—hypothyroidism	0.000749	0.00276	CbGeAlD
Nilotinib—Infection—Liotrix—hypothyroidism	0.000748	0.00346	CcSEcCtD
Nilotinib—HCK—liver—hypothyroidism	0.000746	0.00274	CbGeAlD
Nilotinib—MAPK14—female gonad—hypothyroidism	0.000745	0.00274	CbGeAlD
Nilotinib—EPHA2—adrenal gland—hypothyroidism	0.000743	0.00274	CbGeAlD
Nilotinib—EPHA2—blood—hypothyroidism	0.000743	0.00274	CbGeAlD
Nilotinib—FGR—female gonad—hypothyroidism	0.000742	0.00273	CbGeAlD
Nilotinib—LCK—female gonad—hypothyroidism	0.000742	0.00273	CbGeAlD
Nilotinib—ABL2—liver—hypothyroidism	0.000741	0.00273	CbGeAlD
Nilotinib—Shock—Liotrix—hypothyroidism	0.000741	0.00343	CcSEcCtD
Nilotinib—Tachycardia—Liotrix—hypothyroidism	0.000735	0.0034	CcSEcCtD
Nilotinib—Asthenia—Levothyroxine—hypothyroidism	0.000735	0.0034	CcSEcCtD
Nilotinib—Asthenia—Dextrothyroxine—hypothyroidism	0.000735	0.0034	CcSEcCtD
Nilotinib—CSF1R—cardiovascular system—hypothyroidism	0.000731	0.00269	CbGeAlD
Nilotinib—EPHB4—thyroid gland—hypothyroidism	0.000731	0.00269	CbGeAlD
Nilotinib—Hyperhidrosis—Liotrix—hypothyroidism	0.000728	0.00337	CcSEcCtD
Nilotinib—TEK—adrenal gland—hypothyroidism	0.000725	0.00267	CbGeAlD
Nilotinib—TEK—blood—hypothyroidism	0.000725	0.00267	CbGeAlD
Nilotinib—Pruritus—Dextrothyroxine—hypothyroidism	0.000724	0.00335	CcSEcCtD
Nilotinib—Pruritus—Levothyroxine—hypothyroidism	0.000724	0.00335	CcSEcCtD
Nilotinib—ABL2—cerebellum—hypothyroidism	0.000724	0.00266	CbGeAlD
Nilotinib—Anorexia—Liotrix—hypothyroidism	0.000718	0.00332	CcSEcCtD
Nilotinib—EPHA2—thyroid gland—hypothyroidism	0.000717	0.00264	CbGeAlD
Nilotinib—EPHA4—testis—hypothyroidism	0.000717	0.00264	CbGeAlD
Nilotinib—CA7—cerebellum—hypothyroidism	0.000713	0.00262	CbGeAlD
Nilotinib—PDGFRB—adrenal cortex—hypothyroidism	0.000711	0.00262	CbGeAlD
Nilotinib—CA3—testis—hypothyroidism	0.000708	0.00261	CbGeAlD
Nilotinib—EPHB4—female gonad—hypothyroidism	0.000707	0.0026	CbGeAlD
Nilotinib—Hypotension—Liotrix—hypothyroidism	0.000704	0.00326	CcSEcCtD
Nilotinib—KIT—heart—hypothyroidism	0.000704	0.00259	CbGeAlD
Nilotinib—Diarrhoea—Levothyroxine—hypothyroidism	0.000701	0.00324	CcSEcCtD
Nilotinib—Diarrhoea—Dextrothyroxine—hypothyroidism	0.000701	0.00324	CcSEcCtD
Nilotinib—TEK—thyroid gland—hypothyroidism	0.0007	0.00258	CbGeAlD
Nilotinib—EPHA2—female gonad—hypothyroidism	0.000693	0.00255	CbGeAlD
Nilotinib—EPHB6—adrenal gland—hypothyroidism	0.000693	0.00255	CbGeAlD
Nilotinib—EPHB6—blood—hypothyroidism	0.000693	0.00255	CbGeAlD
Nilotinib—PDGFRB—heart—hypothyroidism	0.000687	0.00253	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.000686	0.00318	CcSEcCtD
Nilotinib—Insomnia—Liotrix—hypothyroidism	0.000681	0.00315	CcSEcCtD
Nilotinib—CA9—testis—hypothyroidism	0.000678	0.0025	CbGeAlD
Nilotinib—Paraesthesia—Liotrix—hypothyroidism	0.000676	0.00313	CcSEcCtD
Nilotinib—TEK—female gonad—hypothyroidism	0.000676	0.00249	CbGeAlD
Nilotinib—Dyspnoea—Liotrix—hypothyroidism	0.000671	0.00311	CcSEcCtD
Nilotinib—CA3—liver—hypothyroidism	0.00067	0.00246	CbGeAlD
Nilotinib—EPHB6—thyroid gland—hypothyroidism	0.000669	0.00246	CbGeAlD
Nilotinib—KIT—cardiovascular system—hypothyroidism	0.000664	0.00244	CbGeAlD
Nilotinib—CSF1R—gonad—hypothyroidism	0.000664	0.00244	CbGeAlD
Nilotinib—MAP2K5—pituitary gland—hypothyroidism	0.000663	0.00244	CbGeAlD
Nilotinib—EPHA4—cerebellum—hypothyroidism	0.000662	0.00244	CbGeAlD
Nilotinib—MAPK14—testis—hypothyroidism	0.000661	0.00243	CbGeAlD
Nilotinib—FGR—testis—hypothyroidism	0.000658	0.00242	CbGeAlD
Nilotinib—LCK—testis—hypothyroidism	0.000658	0.00242	CbGeAlD
Nilotinib—PDGFRA—adrenal gland—hypothyroidism	0.000657	0.00242	CbGeAlD
Nilotinib—PDGFRA—blood—hypothyroidism	0.000657	0.00242	CbGeAlD
Nilotinib—Decreased appetite—Liotrix—hypothyroidism	0.000655	0.00303	CcSEcCtD
Nilotinib—Vomiting—Levothyroxine—hypothyroidism	0.000651	0.00301	CcSEcCtD
Nilotinib—Vomiting—Dextrothyroxine—hypothyroidism	0.000651	0.00301	CcSEcCtD
Nilotinib—Fatigue—Liotrix—hypothyroidism	0.000649	0.00301	CcSEcCtD
Nilotinib—PDGFRB—cardiovascular system—hypothyroidism	0.000649	0.00239	CbGeAlD
Nilotinib—CSF1R—pituitary gland—hypothyroidism	0.000647	0.00238	CbGeAlD
Nilotinib—EPHB6—female gonad—hypothyroidism	0.000646	0.00238	CbGeAlD
Nilotinib—Rash—Dextrothyroxine—hypothyroidism	0.000646	0.00299	CcSEcCtD
Nilotinib—Rash—Levothyroxine—hypothyroidism	0.000646	0.00299	CcSEcCtD
Nilotinib—Dermatitis—Levothyroxine—hypothyroidism	0.000645	0.00299	CcSEcCtD
Nilotinib—Dermatitis—Dextrothyroxine—hypothyroidism	0.000645	0.00299	CcSEcCtD
Nilotinib—Constipation—Liotrix—hypothyroidism	0.000644	0.00298	CcSEcCtD
Nilotinib—CA1—heart—hypothyroidism	0.000644	0.00237	CbGeAlD
Nilotinib—Headache—Dextrothyroxine—hypothyroidism	0.000641	0.00297	CcSEcCtD
Nilotinib—Headache—Levothyroxine—hypothyroidism	0.000641	0.00297	CcSEcCtD
Nilotinib—PDGFRA—thyroid gland—hypothyroidism	0.000634	0.00233	CbGeAlD
Nilotinib—ABL1—adrenal cortex—hypothyroidism	0.000633	0.00233	CbGeAlD
Nilotinib—EPHB4—testis—hypothyroidism	0.000627	0.00231	CbGeAlD
Nilotinib—UGT1A1—blood—hypothyroidism	0.000627	0.00231	CbGeAlD
Nilotinib—CA9—cerebellum—hypothyroidism	0.000626	0.0023	CbGeAlD
Nilotinib—MAPK14—liver—hypothyroidism	0.000625	0.0023	CbGeAlD
Nilotinib—LCK—liver—hypothyroidism	0.000622	0.00229	CbGeAlD
Nilotinib—FGR—liver—hypothyroidism	0.000622	0.00229	CbGeAlD
Nilotinib—Feeling abnormal—Liotrix—hypothyroidism	0.000621	0.00287	CcSEcCtD
Nilotinib—Gastrointestinal pain—Liotrix—hypothyroidism	0.000616	0.00285	CcSEcCtD
Nilotinib—EPHA2—testis—hypothyroidism	0.000615	0.00226	CbGeAlD
Nilotinib—PDGFRA—female gonad—hypothyroidism	0.000613	0.00225	CbGeAlD
Nilotinib—ABL1—heart—hypothyroidism	0.000613	0.00225	CbGeAlD
Nilotinib—MAPK14—cerebellum—hypothyroidism	0.000611	0.00225	CbGeAlD
Nilotinib—Nausea—Levothyroxine—hypothyroidism	0.000608	0.00282	CcSEcCtD
Nilotinib—Nausea—Dextrothyroxine—hypothyroidism	0.000608	0.00282	CcSEcCtD
Nilotinib—CA14—liver—hypothyroidism	0.000608	0.00224	CbGeAlD
Nilotinib—CA1—cardiovascular system—hypothyroidism	0.000607	0.00224	CbGeAlD
Nilotinib—KIT—gonad—hypothyroidism	0.000603	0.00222	CbGeAlD
Nilotinib—TEK—testis—hypothyroidism	0.0006	0.00221	CbGeAlD
Nilotinib—Urticaria—Liotrix—hypothyroidism	0.000598	0.00277	CcSEcCtD
Nilotinib—Body temperature increased—Liotrix—hypothyroidism	0.000595	0.00276	CcSEcCtD
Nilotinib—Abdominal pain—Liotrix—hypothyroidism	0.000595	0.00276	CcSEcCtD
Nilotinib—CA14—cerebellum—hypothyroidism	0.000594	0.00219	CbGeAlD
Nilotinib—MAP2K5—adrenal gland—hypothyroidism	0.000593	0.00218	CbGeAlD
Nilotinib—MAP2K5—blood—hypothyroidism	0.000593	0.00218	CbGeAlD
Nilotinib—EPHB4—liver—hypothyroidism	0.000592	0.00218	CbGeAlD
Nilotinib—PDGFRB—gonad—hypothyroidism	0.000589	0.00217	CbGeAlD
Nilotinib—KIT—pituitary gland—hypothyroidism	0.000588	0.00216	CbGeAlD
Nilotinib—EPHA2—liver—hypothyroidism	0.000581	0.00214	CbGeAlD
Nilotinib—EPHB4—cerebellum—hypothyroidism	0.000579	0.00213	CbGeAlD
Nilotinib—CSF1R—adrenal gland—hypothyroidism	0.000578	0.00213	CbGeAlD
Nilotinib—CSF1R—blood—hypothyroidism	0.000578	0.00213	CbGeAlD
Nilotinib—ABL1—cardiovascular system—hypothyroidism	0.000578	0.00213	CbGeAlD
Nilotinib—PDGFRB—pituitary gland—hypothyroidism	0.000574	0.00211	CbGeAlD
Nilotinib—EPHB6—testis—hypothyroidism	0.000573	0.00211	CbGeAlD
Nilotinib—MAP2K5—thyroid gland—hypothyroidism	0.000572	0.0021	CbGeAlD
Nilotinib—TEK—liver—hypothyroidism	0.000567	0.00209	CbGeAlD
Nilotinib—CSF1R—thyroid gland—hypothyroidism	0.000558	0.00205	CbGeAlD
Nilotinib—Hypersensitivity—Liotrix—hypothyroidism	0.000555	0.00257	CcSEcCtD
Nilotinib—TEK—cerebellum—hypothyroidism	0.000554	0.00204	CbGeAlD
Nilotinib—MAP2K5—female gonad—hypothyroidism	0.000553	0.00203	CbGeAlD
Nilotinib—PDGFRA—testis—hypothyroidism	0.000543	0.002	CbGeAlD
Nilotinib—Asthenia—Liotrix—hypothyroidism	0.00054	0.0025	CcSEcCtD
Nilotinib—CSF1R—female gonad—hypothyroidism	0.000539	0.00198	CbGeAlD
Nilotinib—Pruritus—Liotrix—hypothyroidism	0.000533	0.00247	CcSEcCtD
Nilotinib—EPHB6—cerebellum—hypothyroidism	0.000529	0.00195	CbGeAlD
Nilotinib—KIT—adrenal gland—hypothyroidism	0.000525	0.00193	CbGeAlD
Nilotinib—KIT—blood—hypothyroidism	0.000525	0.00193	CbGeAlD
Nilotinib—ABL1—gonad—hypothyroidism	0.000525	0.00193	CbGeAlD
Nilotinib—Diarrhoea—Liotrix—hypothyroidism	0.000515	0.00239	CcSEcCtD
Nilotinib—PDGFRA—liver—hypothyroidism	0.000514	0.00189	CbGeAlD
Nilotinib—PDGFRB—adrenal gland—hypothyroidism	0.000513	0.00189	CbGeAlD
Nilotinib—PDGFRB—blood—hypothyroidism	0.000513	0.00189	CbGeAlD
Nilotinib—ABL1—pituitary gland—hypothyroidism	0.000512	0.00188	CbGeAlD
Nilotinib—KIT—thyroid gland—hypothyroidism	0.000507	0.00187	CbGeAlD
Nilotinib—CA4—heart—hypothyroidism	0.000503	0.00185	CbGeAlD
Nilotinib—PDGFRA—cerebellum—hypothyroidism	0.000502	0.00185	CbGeAlD
Nilotinib—Dizziness—Liotrix—hypothyroidism	0.000498	0.00231	CcSEcCtD
Nilotinib—PDGFRB—thyroid gland—hypothyroidism	0.000495	0.00182	CbGeAlD
Nilotinib—MAP2K5—testis—hypothyroidism	0.00049	0.0018	CbGeAlD
Nilotinib—UGT1A1—liver—hypothyroidism	0.00049	0.0018	CbGeAlD
Nilotinib—KIT—female gonad—hypothyroidism	0.00049	0.0018	CbGeAlD
Nilotinib—CA1—blood—hypothyroidism	0.00048	0.00177	CbGeAlD
Nilotinib—Vomiting—Liotrix—hypothyroidism	0.000479	0.00222	CcSEcCtD
Nilotinib—CSF1R—testis—hypothyroidism	0.000478	0.00176	CbGeAlD
Nilotinib—PDGFRB—female gonad—hypothyroidism	0.000478	0.00176	CbGeAlD
Nilotinib—Rash—Liotrix—hypothyroidism	0.000475	0.0022	CcSEcCtD
Nilotinib—CA4—cardiovascular system—hypothyroidism	0.000475	0.00175	CbGeAlD
Nilotinib—Dermatitis—Liotrix—hypothyroidism	0.000474	0.0022	CcSEcCtD
Nilotinib—Headache—Liotrix—hypothyroidism	0.000472	0.00218	CcSEcCtD
Nilotinib—MAP2K5—liver—hypothyroidism	0.000463	0.00171	CbGeAlD
Nilotinib—ABL1—adrenal gland—hypothyroidism	0.000457	0.00168	CbGeAlD
Nilotinib—ABL1—blood—hypothyroidism	0.000457	0.00168	CbGeAlD
Nilotinib—MAP2K5—cerebellum—hypothyroidism	0.000453	0.00167	CbGeAlD
Nilotinib—CSF1R—liver—hypothyroidism	0.000452	0.00166	CbGeAlD
Nilotinib—Nausea—Liotrix—hypothyroidism	0.000447	0.00207	CcSEcCtD
Nilotinib—CSF1R—cerebellum—hypothyroidism	0.000442	0.00163	CbGeAlD
Nilotinib—ABL1—thyroid gland—hypothyroidism	0.000441	0.00162	CbGeAlD
Nilotinib—KIT—testis—hypothyroidism	0.000434	0.0016	CbGeAlD
Nilotinib—CA2—adrenal cortex—hypothyroidism	0.000431	0.00159	CbGeAlD
Nilotinib—ABL1—female gonad—hypothyroidism	0.000426	0.00157	CbGeAlD
Nilotinib—PDGFRB—testis—hypothyroidism	0.000424	0.00156	CbGeAlD
Nilotinib—CA4—pituitary gland—hypothyroidism	0.00042	0.00155	CbGeAlD
Nilotinib—CA2—heart—hypothyroidism	0.000417	0.00154	CbGeAlD
Nilotinib—KIT—liver—hypothyroidism	0.000411	0.00151	CbGeAlD
Nilotinib—KIT—cerebellum—hypothyroidism	0.000401	0.00148	CbGeAlD
Nilotinib—PDGFRB—liver—hypothyroidism	0.000401	0.00148	CbGeAlD
Nilotinib—ABCG2—adrenal cortex—hypothyroidism	0.000399	0.00147	CbGeAlD
Nilotinib—CA2—cardiovascular system—hypothyroidism	0.000394	0.00145	CbGeAlD
Nilotinib—PDGFRB—cerebellum—hypothyroidism	0.000392	0.00144	CbGeAlD
Nilotinib—ABCG2—heart—hypothyroidism	0.000386	0.00142	CbGeAlD
Nilotinib—ABL1—testis—hypothyroidism	0.000378	0.00139	CbGeAlD
Nilotinib—CA1—liver—hypothyroidism	0.000376	0.00138	CbGeAlD
Nilotinib—CA4—adrenal gland—hypothyroidism	0.000375	0.00138	CbGeAlD
Nilotinib—CA4—blood—hypothyroidism	0.000375	0.00138	CbGeAlD
Nilotinib—CYP2B6—adrenal cortex—hypothyroidism	0.000369	0.00136	CbGeAlD
Nilotinib—CA4—thyroid gland—hypothyroidism	0.000362	0.00133	CbGeAlD
Nilotinib—ABL1—liver—hypothyroidism	0.000357	0.00132	CbGeAlD
Nilotinib—CYP2B6—heart—hypothyroidism	0.000356	0.00131	CbGeAlD
Nilotinib—CYP2C9—heart—hypothyroidism	0.000353	0.0013	CbGeAlD
Nilotinib—CA4—female gonad—hypothyroidism	0.00035	0.00129	CbGeAlD
Nilotinib—ABL1—cerebellum—hypothyroidism	0.000349	0.00129	CbGeAlD
Nilotinib—CA2—pituitary gland—hypothyroidism	0.000349	0.00128	CbGeAlD
Nilotinib—CYP2B6—cardiovascular system—hypothyroidism	0.000336	0.00124	CbGeAlD
Nilotinib—CYP2C9—cardiovascular system—hypothyroidism	0.000333	0.00123	CbGeAlD
Nilotinib—CYP2C8—pituitary gland—hypothyroidism	0.000332	0.00122	CbGeAlD
Nilotinib—ABCG2—pituitary gland—hypothyroidism	0.000323	0.00119	CbGeAlD
Nilotinib—CA2—adrenal gland—hypothyroidism	0.000311	0.00115	CbGeAlD
Nilotinib—CA2—blood—hypothyroidism	0.000311	0.00115	CbGeAlD
Nilotinib—CA4—testis—hypothyroidism	0.000311	0.00114	CbGeAlD
Nilotinib—CYP2B6—gonad—hypothyroidism	0.000305	0.00112	CbGeAlD
Nilotinib—CA2—thyroid gland—hypothyroidism	0.0003	0.00111	CbGeAlD
Nilotinib—CYP2C8—blood—hypothyroidism	0.000296	0.00109	CbGeAlD
Nilotinib—CA2—female gonad—hypothyroidism	0.00029	0.00107	CbGeAlD
Nilotinib—ABCG2—adrenal gland—hypothyroidism	0.000288	0.00106	CbGeAlD
Nilotinib—ABCG2—blood—hypothyroidism	0.000288	0.00106	CbGeAlD
Nilotinib—CA4—cerebellum—hypothyroidism	0.000287	0.00106	CbGeAlD
Nilotinib—ABCG2—thyroid gland—hypothyroidism	0.000278	0.00102	CbGeAlD
Nilotinib—ABCG2—female gonad—hypothyroidism	0.000269	0.000989	CbGeAlD
Nilotinib—CYP2B6—adrenal gland—hypothyroidism	0.000266	0.000979	CbGeAlD
Nilotinib—CYP2B6—blood—hypothyroidism	0.000266	0.000979	CbGeAlD
Nilotinib—CYP2C9—blood—hypothyroidism	0.000263	0.000969	CbGeAlD
Nilotinib—CA2—testis—hypothyroidism	0.000257	0.000948	CbGeAlD
Nilotinib—CYP2C8—testis—hypothyroidism	0.000245	0.000903	CbGeAlD
Nilotinib—CA2—liver—hypothyroidism	0.000243	0.000896	CbGeAlD
Nilotinib—ABCG2—testis—hypothyroidism	0.000238	0.000878	CbGeAlD
Nilotinib—CA2—cerebellum—hypothyroidism	0.000238	0.000875	CbGeAlD
Nilotinib—CYP2C8—liver—hypothyroidism	0.000232	0.000853	CbGeAlD
Nilotinib—ABCG2—liver—hypothyroidism	0.000225	0.00083	CbGeAlD
Nilotinib—ABCG2—cerebellum—hypothyroidism	0.00022	0.00081	CbGeAlD
Nilotinib—CYP2B6—testis—hypothyroidism	0.00022	0.00081	CbGeAlD
Nilotinib—CYP2B6—liver—hypothyroidism	0.000208	0.000765	CbGeAlD
Nilotinib—CYP2C9—liver—hypothyroidism	0.000206	0.000758	CbGeAlD
Nilotinib—CYP3A4—blood—hypothyroidism	0.000201	0.000739	CbGeAlD
Nilotinib—CYP2D6—blood—hypothyroidism	0.000198	0.000727	CbGeAlD
Nilotinib—ABCB1—adrenal cortex—hypothyroidism	0.000197	0.000725	CbGeAlD
Nilotinib—ABCB1—heart—hypothyroidism	0.00019	0.000701	CbGeAlD
Nilotinib—CYP2D6—female gonad—hypothyroidism	0.000184	0.000678	CbGeAlD
Nilotinib—ABCB1—cardiovascular system—hypothyroidism	0.00018	0.000662	CbGeAlD
Nilotinib—CYP2D6—testis—hypothyroidism	0.000163	0.000602	CbGeAlD
Nilotinib—ABCB1—gonad—hypothyroidism	0.000163	0.0006	CbGeAlD
Nilotinib—ABCB1—pituitary gland—hypothyroidism	0.000159	0.000586	CbGeAlD
Nilotinib—CYP3A4—liver—hypothyroidism	0.000157	0.000578	CbGeAlD
Nilotinib—CYP2D6—liver—hypothyroidism	0.000155	0.000569	CbGeAlD
Nilotinib—CYP2D6—cerebellum—hypothyroidism	0.000151	0.000556	CbGeAlD
Nilotinib—ABCB1—adrenal gland—hypothyroidism	0.000142	0.000523	CbGeAlD
Nilotinib—ABCB1—blood—hypothyroidism	0.000142	0.000523	CbGeAlD
Nilotinib—ABCB1—thyroid gland—hypothyroidism	0.000137	0.000505	CbGeAlD
Nilotinib—ABCB1—female gonad—hypothyroidism	0.000133	0.000488	CbGeAlD
Nilotinib—ABCB1—testis—hypothyroidism	0.000118	0.000433	CbGeAlD
Nilotinib—ABCB1—liver—hypothyroidism	0.000111	0.000409	CbGeAlD
Nilotinib—ABCB1—cerebellum—hypothyroidism	0.000109	0.0004	CbGeAlD
Nilotinib—MAPK8—Signaling Pathways—CLTC—hypothyroidism	7.57e-05	0.000358	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—THRB—hypothyroidism	7.55e-05	0.000357	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—VAV3—hypothyroidism	7.55e-05	0.000357	CbGpPWpGaD
Nilotinib—LYN—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	7.54e-05	0.000356	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—SH2B3—hypothyroidism	7.54e-05	0.000356	CbGpPWpGaD
Nilotinib—CA1—Metabolism—TSHB—hypothyroidism	7.48e-05	0.000353	CbGpPWpGaD
Nilotinib—CA3—Metabolism—POMC—hypothyroidism	7.36e-05	0.000348	CbGpPWpGaD
Nilotinib—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	7.3e-05	0.000345	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PIK3C2A—hypothyroidism	7.25e-05	0.000343	CbGpPWpGaD
Nilotinib—CYP2C9—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	7.23e-05	0.000342	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CLTC—hypothyroidism	7.2e-05	0.00034	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	7.18e-05	0.000339	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—TPO—hypothyroidism	7.18e-05	0.000339	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CLTC—hypothyroidism	7.17e-05	0.000339	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	7.15e-05	0.000338	CbGpPWpGaD
Nilotinib—LYN—Immune System—CLTC—hypothyroidism	7.02e-05	0.000332	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CLTC—hypothyroidism	6.99e-05	0.00033	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PIK3C2A—hypothyroidism	6.95e-05	0.000329	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—VAV3—hypothyroidism	6.81e-05	0.000322	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PIK3C2A—hypothyroidism	6.66e-05	0.000315	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CLTC—hypothyroidism	6.66e-05	0.000315	CbGpPWpGaD
Nilotinib—HCK—Immune System—PRL—hypothyroidism	6.58e-05	0.000311	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—IYD—hypothyroidism	6.58e-05	0.000311	CbGpPWpGaD
Nilotinib—CA9—Metabolism—TSHB—hypothyroidism	6.57e-05	0.000311	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TRH—hypothyroidism	6.54e-05	0.000309	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—IGF1—hypothyroidism	6.46e-05	0.000305	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—VAV3—hypothyroidism	6.44e-05	0.000305	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—VAV3—hypothyroidism	6.44e-05	0.000304	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—VAV3—hypothyroidism	6.41e-05	0.000303	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—VAV3—hypothyroidism	6.31e-05	0.000298	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—VAV3—hypothyroidism	6.28e-05	0.000297	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TRH—hypothyroidism	6.22e-05	0.000294	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	6.18e-05	0.000292	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—VAV3—hypothyroidism	6.1e-05	0.000288	CbGpPWpGaD
Nilotinib—HCK—Immune System—VAV3—hypothyroidism	6.09e-05	0.000288	CbGpPWpGaD
Nilotinib—CA4—Metabolism—SLC5A5—hypothyroidism	6.09e-05	0.000288	CbGpPWpGaD
Nilotinib—HCK—Disease—PRL—hypothyroidism	6.08e-05	0.000287	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CLTC—hypothyroidism	6.03e-05	0.000285	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—VAV3—hypothyroidism	5.98e-05	0.000283	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CLTC—hypothyroidism	5.98e-05	0.000282	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—PRL—hypothyroidism	5.96e-05	0.000282	CbGpPWpGaD
Nilotinib—BLK—Immune System—PRL—hypothyroidism	5.96e-05	0.000282	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	5.95e-05	0.000281	CbGpPWpGaD
Nilotinib—FGR—Immune System—PRL—hypothyroidism	5.94e-05	0.000281	CbGpPWpGaD
Nilotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	5.89e-05	0.000278	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PIK3C2A—hypothyroidism	5.86e-05	0.000277	CbGpPWpGaD
Nilotinib—CA2—Metabolism—SLC5A5—hypothyroidism	5.84e-05	0.000276	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TSHR—hypothyroidism	5.83e-05	0.000276	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TSHB—hypothyroidism	5.83e-05	0.000276	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—VAV3—hypothyroidism	5.8e-05	0.000274	CbGpPWpGaD
Nilotinib—LCK—Immune System—CLTC—hypothyroidism	5.76e-05	0.000272	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—VAV3—hypothyroidism	5.68e-05	0.000269	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—VAV3—hypothyroidism	5.66e-05	0.000267	CbGpPWpGaD
Nilotinib—CA1—Metabolism—SLC5A5—hypothyroidism	5.6e-05	0.000265	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ATP5O—hypothyroidism	5.59e-05	0.000264	CbGpPWpGaD
Nilotinib—CYP2B6—Biological oxidations—POMC—hypothyroidism	5.58e-05	0.000264	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—IYD—hypothyroidism	5.57e-05	0.000263	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TSHB—hypothyroidism	5.55e-05	0.000262	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TSHR—hypothyroidism	5.55e-05	0.000262	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—VAV3—hypothyroidism	5.52e-05	0.000261	CbGpPWpGaD
Nilotinib—BLK—Immune System—VAV3—hypothyroidism	5.52e-05	0.000261	CbGpPWpGaD
Nilotinib—FGR—Immune System—VAV3—hypothyroidism	5.5e-05	0.00026	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CLTC—hypothyroidism	5.44e-05	0.000257	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—VAV3—hypothyroidism	5.39e-05	0.000255	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	5.31e-05	0.000251	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TPO—hypothyroidism	5.26e-05	0.000249	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TRH—hypothyroidism	5.21e-05	0.000246	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SH2B3—hypothyroidism	5.2e-05	0.000246	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—VAV3—hypothyroidism	5.17e-05	0.000245	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TRH—hypothyroidism	5.16e-05	0.000244	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CLTC—hypothyroidism	5.15e-05	0.000243	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SH2B3—hypothyroidism	4.94e-05	0.000234	CbGpPWpGaD
Nilotinib—CA9—Metabolism—SLC5A5—hypothyroidism	4.92e-05	0.000233	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—IYD—hypothyroidism	4.85e-05	0.000229	CbGpPWpGaD
Nilotinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	4.77e-05	0.000226	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—PRL—hypothyroidism	4.75e-05	0.000225	CbGpPWpGaD
Nilotinib—CA14—Metabolism—POMC—hypothyroidism	4.74e-05	0.000224	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ATP5O—hypothyroidism	4.74e-05	0.000224	CbGpPWpGaD
Nilotinib—CYP2C8—Biological oxidations—POMC—hypothyroidism	4.72e-05	0.000223	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TRH—hypothyroidism	4.7e-05	0.000222	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—VAV3—hypothyroidism	4.66e-05	0.00022	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TSHB—hypothyroidism	4.65e-05	0.00022	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TSHR—hypothyroidism	4.65e-05	0.00022	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CLTC—hypothyroidism	4.64e-05	0.000219	CbGpPWpGaD
Nilotinib—CA6—Metabolism—POMC—hypothyroidism	4.62e-05	0.000218	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TSHR—hypothyroidism	4.6e-05	0.000218	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TSHB—hypothyroidism	4.6e-05	0.000218	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—IYD—hypothyroidism	4.57e-05	0.000216	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CLTC—hypothyroidism	4.54e-05	0.000215	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—IYD—hypothyroidism	4.53e-05	0.000214	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TPO—hypothyroidism	4.45e-05	0.00021	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TRH—hypothyroidism	4.45e-05	0.00021	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—VAV3—hypothyroidism	4.4e-05	0.000208	CbGpPWpGaD
Nilotinib—BRAF—Disease—PRL—hypothyroidism	4.35e-05	0.000205	CbGpPWpGaD
Nilotinib—CA7—Metabolism—POMC—hypothyroidism	4.31e-05	0.000204	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CLTC—hypothyroidism	4.31e-05	0.000203	CbGpPWpGaD
Nilotinib—KIT—Immune System—PRL—hypothyroidism	4.29e-05	0.000203	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TSHB—hypothyroidism	4.19e-05	0.000198	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TSHR—hypothyroidism	4.19e-05	0.000198	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—AVP—hypothyroidism	4.18e-05	0.000198	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SH2B3—hypothyroidism	4.14e-05	0.000196	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ATP5O—hypothyroidism	4.13e-05	0.000195	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	4.13e-05	0.000195	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SH2B3—hypothyroidism	4.1e-05	0.000194	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PRL—hypothyroidism	4.06e-05	0.000192	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TRH—hypothyroidism	4.01e-05	0.000189	CbGpPWpGaD
Nilotinib—CA12—Metabolism—POMC—hypothyroidism	4e-05	0.000189	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TSHR—hypothyroidism	3.97e-05	0.000187	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TSHB—hypothyroidism	3.97e-05	0.000187	CbGpPWpGaD
Nilotinib—KIT—Immune System—VAV3—hypothyroidism	3.96e-05	0.000187	CbGpPWpGaD
Nilotinib—KIT—Disease—PRL—hypothyroidism	3.96e-05	0.000187	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TRH—hypothyroidism	3.93e-05	0.000186	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—TSHB—hypothyroidism	3.92e-05	0.000185	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ATP5O—hypothyroidism	3.89e-05	0.000184	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—IGF1—hypothyroidism	3.89e-05	0.000184	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TPO—hypothyroidism	3.88e-05	0.000183	CbGpPWpGaD
Nilotinib—CYP2D6—Biological oxidations—POMC—hypothyroidism	3.88e-05	0.000183	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—IGF1—hypothyroidism	3.87e-05	0.000183	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PRL—hypothyroidism	3.86e-05	0.000182	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ATP5O—hypothyroidism	3.85e-05	0.000182	CbGpPWpGaD
Nilotinib—CYP2C9—Biological oxidations—POMC—hypothyroidism	3.84e-05	0.000182	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—VAV3—hypothyroidism	3.75e-05	0.000177	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PRL—hypothyroidism	3.75e-05	0.000177	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SH2B3—hypothyroidism	3.73e-05	0.000177	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CLTC—hypothyroidism	3.72e-05	0.000176	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TRH—hypothyroidism	3.72e-05	0.000176	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—IGF1—hypothyroidism	3.69e-05	0.000174	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PRL—hypothyroidism	3.67e-05	0.000173	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TPO—hypothyroidism	3.66e-05	0.000173	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PRL—hypothyroidism	3.65e-05	0.000173	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	3.64e-05	0.000172	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TPO—hypothyroidism	3.62e-05	0.000171	CbGpPWpGaD
Nilotinib—LYN—Immune System—PRL—hypothyroidism	3.58e-05	0.000169	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TSHB—hypothyroidism	3.57e-05	0.000169	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TSHR—hypothyroidism	3.57e-05	0.000169	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VAV3—hypothyroidism	3.57e-05	0.000169	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PRL—hypothyroidism	3.56e-05	0.000168	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SH2B3—hypothyroidism	3.54e-05	0.000167	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TSHB—hypothyroidism	3.5e-05	0.000165	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TSHR—hypothyroidism	3.5e-05	0.000165	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3C2A—hypothyroidism	3.49e-05	0.000165	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AVP—hypothyroidism	3.44e-05	0.000162	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VAV3—hypothyroidism	3.39e-05	0.00016	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PRL—hypothyroidism	3.39e-05	0.00016	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—VAV3—hypothyroidism	3.38e-05	0.00016	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PRL—hypothyroidism	3.37e-05	0.000159	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	3.36e-05	0.000159	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—TSHB—hypothyroidism	3.32e-05	0.000157	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TSHB—hypothyroidism	3.32e-05	0.000157	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TSHR—hypothyroidism	3.32e-05	0.000157	CbGpPWpGaD
Nilotinib—LYN—Immune System—VAV3—hypothyroidism	3.31e-05	0.000156	CbGpPWpGaD
Nilotinib—ABL1—Immune System—VAV3—hypothyroidism	3.29e-05	0.000156	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AVP—hypothyroidism	3.27e-05	0.000154	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TRH—hypothyroidism	3.22e-05	0.000152	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IGF1—hypothyroidism	3.19e-05	0.000151	CbGpPWpGaD
Nilotinib—CA4—Metabolism—POMC—hypothyroidism	3.19e-05	0.000151	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SH2B3—hypothyroidism	3.18e-05	0.000151	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—VAV3—hypothyroidism	3.14e-05	0.000148	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SH2B3—hypothyroidism	3.12e-05	0.000147	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PRL—hypothyroidism	3.07e-05	0.000145	CbGpPWpGaD
Nilotinib—CA2—Metabolism—POMC—hypothyroidism	3.05e-05	0.000144	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PRL—hypothyroidism	3.04e-05	0.000144	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—IYD—hypothyroidism	2.99e-05	0.000141	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3C2A—hypothyroidism	2.96e-05	0.00014	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SH2B3—hypothyroidism	2.96e-05	0.00014	CbGpPWpGaD
Nilotinib—LCK—Immune System—PRL—hypothyroidism	2.93e-05	0.000139	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—SLC5A5—hypothyroidism	2.93e-05	0.000139	CbGpPWpGaD
Nilotinib—CA1—Metabolism—POMC—hypothyroidism	2.93e-05	0.000138	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	2.87e-05	0.000136	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TSHB—hypothyroidism	2.87e-05	0.000136	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TSHR—hypothyroidism	2.87e-05	0.000136	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VAV3—hypothyroidism	2.84e-05	0.000134	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VAV3—hypothyroidism	2.82e-05	0.000133	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PRL—hypothyroidism	2.77e-05	0.000131	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AVP—hypothyroidism	2.74e-05	0.000129	CbGpPWpGaD
Nilotinib—LCK—Immune System—VAV3—hypothyroidism	2.71e-05	0.000128	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AVP—hypothyroidism	2.71e-05	0.000128	CbGpPWpGaD
Nilotinib—LCK—Disease—PRL—hypothyroidism	2.71e-05	0.000128	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PRL—hypothyroidism	2.62e-05	0.000124	CbGpPWpGaD
Nilotinib—CA9—Metabolism—POMC—hypothyroidism	2.57e-05	0.000122	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VAV3—hypothyroidism	2.56e-05	0.000121	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SH2B3—hypothyroidism	2.56e-05	0.000121	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ATP5O—hypothyroidism	2.54e-05	0.00012	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—POMC—hypothyroidism	2.53e-05	0.00012	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—SLC5A5—hypothyroidism	2.49e-05	0.000118	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AVP—hypothyroidism	2.47e-05	0.000117	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TSHB—hypothyroidism	2.44e-05	0.000115	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VAV3—hypothyroidism	2.43e-05	0.000115	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TPO—hypothyroidism	2.39e-05	0.000113	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PRL—hypothyroidism	2.36e-05	0.000112	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AVP—hypothyroidism	2.34e-05	0.00011	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PRL—hypothyroidism	2.31e-05	0.000109	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—POMC—hypothyroidism	2.28e-05	0.000108	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	2.26e-05	0.000107	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IGF1—hypothyroidism	2.2e-05	0.000104	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PRL—hypothyroidism	2.19e-05	0.000104	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VAV3—hypothyroidism	2.19e-05	0.000103	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—POMC—hypothyroidism	2.17e-05	0.000103	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3C2A—hypothyroidism	2.17e-05	0.000103	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VAV3—hypothyroidism	2.14e-05	0.000101	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AVP—hypothyroidism	2.11e-05	9.95e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IGF1—hypothyroidism	2.09e-05	9.87e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AVP—hypothyroidism	2.06e-05	9.75e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TSHB—hypothyroidism	2.06e-05	9.74e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VAV3—hypothyroidism	2.03e-05	9.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AVP—hypothyroidism	1.95e-05	9.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PRL—hypothyroidism	1.9e-05	8.96e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	1.84e-05	8.69e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SLC5A5—hypothyroidism	1.82e-05	8.62e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—POMC—hypothyroidism	1.82e-05	8.6e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.81e-05	8.57e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—POMC—hypothyroidism	1.8e-05	8.52e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TSHB—hypothyroidism	1.8e-05	8.49e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VAV3—hypothyroidism	1.75e-05	8.29e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1—hypothyroidism	1.75e-05	8.27e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1—hypothyroidism	1.73e-05	8.2e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TSHB—hypothyroidism	1.69e-05	8e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AVP—hypothyroidism	1.69e-05	7.99e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TSHB—hypothyroidism	1.68e-05	7.93e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—POMC—hypothyroidism	1.64e-05	7.76e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3C2A—hypothyroidism	1.6e-05	7.57e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1—hypothyroidism	1.58e-05	7.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—POMC—hypothyroidism	1.55e-05	7.34e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC5A5—hypothyroidism	1.54e-05	7.29e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—POMC—hypothyroidism	1.53e-05	7.25e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	1.51e-05	7.13e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3C2A—hypothyroidism	1.5e-05	7.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1—hypothyroidism	1.49e-05	7.06e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.48e-05	6.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—POMC—hypothyroidism	1.4e-05	6.61e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—POMC—hypothyroidism	1.37e-05	6.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1—hypothyroidism	1.35e-05	6.36e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC5A5—hypothyroidism	1.34e-05	6.36e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1—hypothyroidism	1.32e-05	6.23e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—POMC—hypothyroidism	1.3e-05	6.15e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—POMC—hypothyroidism	1.3e-05	6.14e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC5A5—hypothyroidism	1.27e-05	5.99e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC5A5—hypothyroidism	1.26e-05	5.94e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1—hypothyroidism	1.25e-05	5.91e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—hypothyroidism	1.12e-05	5.31e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TSHB—hypothyroidism	1.11e-05	5.23e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—hypothyroidism	1.08e-05	5.11e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	9.86e-06	4.66e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—hypothyroidism	9.54e-06	4.51e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC5A5—hypothyroidism	8.28e-06	3.92e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—hypothyroidism	8.07e-06	3.82e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—hypothyroidism	7.03e-06	3.33e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—hypothyroidism	6.63e-06	3.13e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—hypothyroidism	6.57e-06	3.11e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—hypothyroidism	4.33e-06	2.05e-05	CbGpPWpGaD
